in

ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients – FiercePharma

ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients – FiercePharma





ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients – FiercePharma – Healthy Duck















































Skip to content

  1. ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patientsFiercePharma
  2. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomized, double-blind, double-dummy, dose-finding phase 2 studyThe Lancet
  3. View Full Coverage on Google News

.

Categories Medicines Tags ACC 2022, astrazeneca, Bayer, Bristol Myers Squibb, chronic kidney disease, Farxiga, Fierce Pharma Homepage, Invokana, Johnson & Johnson, Kerendia, Pharma, SGLT2 drugs, Xarelto

Source: Culled From Healthy Duck.

It's April And Justin Trudeau Still Has Parliament Locked Down To Push An Anti-Convoy Narrative

It's April And Justin Trudeau Still Has Parliament Locked Down To Push An Anti-Convoy Narrative

Fuudo releases week 1 tier list for Street Fighter 5's Definitive Update

Fuudo releases week 1 tier list for Street Fighter 5's Definitive Update